| 1.34 -0.66 (-33%) | 11-28 13:12 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 6.25  |
1-year : | 9.26 |
| Resists | First : | 5.35 |
Second : | 7.92 |
| Pivot price | 4.48 |
|||
| Supports | First : | 1.2 |
Second : | 0.99 |
| MAs | MA(5) : | 3.32 |
MA(20) : | 4.82 |
| MA(100) : | 7.53 |
MA(250) : | 10.07 |
|
| MACD | MACD : | -1.3 |
Signal : | -1.1 |
| %K %D | K(14,3) : | 1 |
D(3) : | 10.4 |
| RSI | RSI(14): 23.7 |
|||
| 52-week | High : | 41.25 | Low : | 1.2 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AXLA ] has closed below the lower bollinger band by 11.5%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 38.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.36 - 3.38 | 3.38 - 3.4 |
| Low: | 1.96 - 1.98 | 1.98 - 2 |
| Close: | 1.97 - 2 | 2 - 2.02 |
Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.
Tue, 28 Nov 2023
North American Morning Briefing: November Rally Pauses Ahead of ... - Morningstar
Mon, 27 Nov 2023
Axcella Health Inc.(NasdaqGM : AXLA) dropped from S&P TMI Index - Marketscreener.com
Mon, 27 Nov 2023
Healthcare Stocks Moving Up and Down Monday: BDRX, LIXT, ABEO, IRIX, AXLA, HARP, THTX, ABVC - InvestorsObserver
Mon, 27 Nov 2023
How Will the Market React to Axcella Health Inc (AXLA) Stock Getting a Bearish Rating - InvestorsObserver
Thu, 23 Nov 2023
Axcella Health Inc. ($AXLA) Trading Report - Stock Traders Daily
Tue, 31 Oct 2023
Where Will Axcella Health Inc (AXLA) Stock Go Next After It Is Lower By 22.18% in a Week? - InvestorsObserver
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 1.07e+006 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 116 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.13e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -87.7 % |
| Return on Equity (ttm) | -1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 366.5 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -18.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -43 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.77 |
| Dividend | 0 |
| Forward Dividend | 78180 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|